Acne Vulgaris Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand Through 2034

The market size of Acne Vulgaris is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Pelthos Therapeutics, Dermata Therapeutics, Botanix Pharmaceuticals, AOBiome LLC, BioPharmX, Timber Pharmaceuticals

[Nevada, United States] - DelveInsight's "Acne Vulgaris Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Acne Vulgaris, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Acne Vulgaris Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Acne Vulgaris Market Report:
The Acne Vulgaris market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034)
In June, 2024: Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. announced that the primary objective of their study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
In June, 2024: Galderma R&D announced that the purpose of their study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.
In June, 2024: Biofrontera Bioscience GmbH announced that the gal of their study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe Acne vulgaris.
In March, 2024: Sun Pharmaceutical Industries Limited announced that Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination to emulate real life practice.
In 2023, among the 7MM, the US had thehighest number of prevalent cases of acne vulgaris. According to DelveInsight estimates, there were approximately 69 million prevalent cases of acne vulgaris in the US in 2023, which are projected to increase during the forecast period (2024-2034).
In 2023, there were approximately 10 million cases of mild severity, 13 million cases of moderate severity, and 6 million cases of severe severity in the 7MM
In 2023, the gender-specific diagnosed prevalent cases among the EU4 and the accounted for approximately 4.4 million male cases and 6.7 million female cases.
Key Acne Vulgaris Companies are as follow:Pelthos Therapeutics, Dermata Therapeutics, Botanix Pharmaceuticals, AOBiome LLC, BioPharmX, Timber Pharmaceuticals
Key Acne Vulgaris Therapies are as follow: AKLIEF (Trifarotene)/ CD-5789, AMZEEQ (minocycline), ARAZLO (tazarotene), SB204, B244, BPX-01, BTX 1503, Clascoterone, S6G5T-3, S6G5T-8, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide and more...
Launching multiple stage Acne Vulgaris pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Acne Vulgaris market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Acne Vulgaris Overview:
Acne vulgaris, commonly referred to as acne, is a chronic inflammatory prevalent dermatological condition characterized by the occurrence of pimples, blackheads, and whiteheads on the skin. Based on the severity, acne vulgaris can be classified into mild acne (presence of non-inflammatory lesions, such as blackheads and whiteheads), moderate acne (presents with a combination of comedonal and inflammatory lesions, including papules and pustules, with moderate erythema and occasional scarring), and severe acne (presence of extensive inflammatory lesions, including nodules and cysts. scarring, and potential psychological distress).

Acne Vulgaris Drugs Uptake and Pipeline Development Activities:
The drugs uptake section examines the adoption rate of new or anticipated drugs over the study period. This includes market uptake for each drug, patient adoption rates for therapies, and sales figures for each medication. The report also offers insights into Acne Vulgaris Pipeline Development Activities, evaluating therapeutic candidates at different stages and highlighting key companies involved.

For more information about Acne Vulgaris companies working in the treatment market, visit: https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Acne Vulgaris Therapies and Key Companies:
AKLIEF (Trifarotene)/ CD-5789: Galderma S.A.
AMZEEQ (minocycline): Journey Medical Corporation/Vyne Therapeutics Inc.
ARAZLO (tazarotene): Bausch Health Companies Inc. / Ortho Dermatologics
SB204: Pelthos Therapeutics
B244: AOBiome LLC
DMT310: Dermata Therapeutics
BPX-01: Timber Pharmaceuticals/BioPharmX
BTX 1503: Botanix Pharmaceuticals

Acne Vulgaris Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Acne Vulgaris.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Acne Vulgaris Epidemiology Segmentation:
The Acne Vulgaris market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Acne Vulgaris Total Prevalence
Acne Vulgaris Prevalent Cases by severity
Acne Vulgaris Gender-specific Prevalence
Acne Vulgaris Diagnosed Cases of Episodic and Chronic

Acne Vulgaris Market Drivers and Barriers:
The rising prevalence of acne vulgaris due to changes in lifestyle, diet, increased psychological stress, and hormonal changes, especially in the adolescent population, creates a larger market demand for the treatment of acne vulgaris.
Technological developments in skincare and dermatological therapies have improved patient outcomes and treatment efficacy, enabling precise approaches to patient care and efficient therapies due to the chronic nature of acne.
The adverse effects of acne treatments, such as dryness,irritation, or allergic responses, make patients lesscompliant. Additionally, severe irritation or infrequencyin allergic reactions are majorly brought on byconventional acne products only.
Prolonged and frequent use of these antibiotics in thetreatment of acne vulgaris often results in an increase inbacterial resistance, which limits the effectiveness ofantibiotic treatment.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Acne Vulgaris Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Acne Vulgaris Companies: Pelthos Therapeutics, Dermata Therapeutics, Botanix Pharmaceuticals, AOBiome LLC, BioPharmX, Timber Pharmaceuticals
Key Acne Vulgaris Therapies: AKLIEF (Trifarotene)/ CD-5789, AMZEEQ (minocycline), ARAZLO (tazarotene), SB204, B244, BPX-01, BTX 1503, Clascoterone, S6G5T-3, S6G5T-8, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide and more...
Acne Vulgaris Therapeutic Assessment: Current marketed and emerging therapies
Acne Vulgaris Market Dynamics: Acne Vulgaris Market drivers and Acne Vulgaris barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acne Vulgaris Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Acne Vulgaris market outlook, drug uptake, treatment scenario, and epidemiology trends: https://www.delveinsight.com/sample-request/acne-vulgaris-av-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Acne Vulgaris Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. Acne Vulgaris: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

List of TOP Selling Inhibitors Market Research Report as of 2024:

CTLA-4 Inhibitors Market: https://www.delveinsight.com/report-store/ctla4-inhibitors-market-forecast
VEGF Inhibitors Market: https://www.delveinsight.com/report-store/vegf-inhibitors-market-forecast
TROP-2 Inhibitors Market: https://www.delveinsight.com/report-store/trop2-inhibitors-market-forecast
HER2+ Market: https://www.delveinsight.com/report-store/her2-positive-market-forecast
HER3+ Market: https://www.delveinsight.com/report-store/her3-positive-market-forecast
FTase Inhibitors Market: https://www.delveinsight.com/report-store/ftase-inhibitors-market-forecast
Bispecifics Market: https://www.delveinsight.com/report-store/bispecifics-market-forecast
CAR-T Market: https://www.delveinsight.com/report-store/car-t-market-forecast
CD-19 Market: https://www.delveinsight.com/report-store/cd19-market-forecast
CD-20 Market: https://www.delveinsight.com/report-store/cd20-market-forecast
CD-38 Market: https://www.delveinsight.com/report-store/cd38-market-forecast
TP-53 Market: https://www.delveinsight.com/report-store/tp53-market-forecast
NTRK Market: https://www.delveinsight.com/report-store/ntrk-market-forecast
BRCA Market: https://www.delveinsight.com/report-store/brca-market-forecast
SMAD4/DPC4 Market: https://www.delveinsight.com/report-store/smad4-dpc4-market-forecast
Connective Tissue Growth Factor (CTGF) Inhibitors Market: https://www.delveinsight.com/report-store/connective-tissue-growth-factor-ctgf-inhibitors-market-forecast
Selective Inhibitor of the CXCR4 Chemokine Receptor Market: https://www.delveinsight.com/report-store/selective-inhibitor-of-the-cxcr4-chemokine-receptor-market-forecast
PI3K Market: https://www.delveinsight.com/report-store/pi3k-market-forecast
FGFR Market: https://www.delveinsight.com/report-store/fgfr-market-forecast
PROTAC Market: https://www.delveinsight.com/report-store/protac-market-forecast
CEACAM5 Market: https://www.delveinsight.com/report-store/ceacam5-market-forecast
Anti Cancer Vaccine Market: https://www.delveinsight.com/report-store/anti-cancer-vaccine-market-forecast
Androgen Receptor Inhibitor Market: https://www.delveinsight.com/report-store/androgen-receptor-inhibitor-market-forecast
GnRH Receptor Antagonist Market: https://www.delveinsight.com/report-store/gnrh-receptor-antagonist-market-forecast
CDK4/6 Inhibitor Market: https://www.delveinsight.com/report-store/cdk4-6-inhibitor-market-forecast
SERD Market: https://www.delveinsight.com/report-store/serd-market-forecast
AKT Inhibitor Market: https://www.delveinsight.com/report-store/akt-inhibitor-market-forecast
Radioligand Therapies Market: https://www.delveinsight.com/report-store/radioligand-therapies-market-forecast
B7-H3 Market: https://www.delveinsight.com/report-store/b7-h3-market-forecast
CYP17 Inhibitor Market: https://www.delveinsight.com/report-store/cyp17-inhibitor-market-forecast
NTD AR Inhibitor Market: https://www.delveinsight.com/report-store/ntd-ar-inhibitor-market-forecast
NRG fusion Market: https://www.delveinsight.com/report-store/nrg-fusion-market-forecast
AXL Receptor Tyrosine Kinase Inhibitors Market: https://www.delveinsight.com/report-store/axl-receptor-tyrosine-kinase-inhibitors-market-forecast
PSMA-Targeted Therapy Market: https://www.delveinsight.com/report-store/psma-targeted-therapy-market-forecast
EGFR Market: https://www.delveinsight.com/report-store/egfr-market-forecast
ALK Market: https://www.delveinsight.com/report-store/alk-market-forecast
BRAF Market: https://www.delveinsight.com/report-store/braf-market-forecast
ERBB 2 Receptor Antagonists Market: https://www.delveinsight.com/report-store/erbb2-receptor-antagonists-market-forecast
VEGFR-2 Inhibitor Market: https://www.delveinsight.com/report-store/vegfr2-inhibitor-market-forecast
Thymidine Phosphorylase Inhibitors Market: https://www.delveinsight.com/report-store/thymidine-phosphorylase-inhibitors-market-forecast
DNA Synthesis Inhibitor Market: https://www.delveinsight.com/report-store/dna-synthesis-inhibitor-market-forecast
CD223 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd223-antigen-inhibitors-market-forecast
BTK Inhibitors Market: https://www.delveinsight.com/report-store/btk-inhibitors-market-forecast
SERMS Market: https://www.delveinsight.com/report-store/serms-market-forecast
PLK1 Inhibitor Market: https://www.delveinsight.com/report-store/plk1-inhibitor-market-forecast
CD47 Antigen Inhibitors Market: https://www.delveinsight.com/report-store/cd47-antigen-inhibitors-market-forecast
RET Fusion Market: https://www.delveinsight.com/report-store/ret-fusion-market-forecast
ROS-1 Market: https://www.delveinsight.com/report-store/ros1-market-forecast
Mesenchymal-epithelial Transition Factor (MET) Market: https://www.delveinsight.com/report-store/mesenchymal-epithelial-transition-factor-met-market-forecast
MET Kinase Inhibitor Market: https://www.delveinsight.com/report-store/met-kinase-inhibitor-market-forecast

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.